PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23899439-2	2013	A Phase I open-label pharmacokinetic (PK) study was performed to describe first dose (PK1) and steady-state (PK2) PKs of the integrase inhibitor dolutegravir (DTG) in blood plasma (BP), cervicovaginal fluid (CVF), cervical tissue (CT) and vaginal tissue (VT) in HIV type-1-negative women.	dolutegravir	145-157	prokineticin 2	Homo sapiens	109-112	
23899439-11	2013	Accumulation of DTG from PK1 to PK2 occurred in BP, CT and VT, but only marginally in CVF.	dolutegravir	16-19	prokineticin 2	Homo sapiens	32-35	
23899439-14	2013	At PK2, DTG accumulated to a greater extent in tissue than in BP or CVF, suggesting increased tissue affinity.	dolutegravir	8-11	prokineticin 2	Homo sapiens	3-6